Cargando…
Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study
AIM OF THE STUDY: To optimize the long-term outcomes of patients with non-alcoholic fatty liver disease (NAFLD), long-term therapy is important to prevent cirrhosis and hepatocellular carcinoma. Pemafibrate, a novel selective peroxisome proliferator-activated receptor-α modulator, is a promising the...
Autores principales: | Shinozaki, Satoshi, Tahara, Toshiyuki, Lefor, Alan Kawarai, Ogura, Masahito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284174/ https://www.ncbi.nlm.nih.gov/pubmed/34295984 http://dx.doi.org/10.5114/ceh.2021.106864 |
Ejemplares similares
-
Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease
por: Shinozaki, Satoshi, et al.
Publicado: (2020) -
Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients
por: Shinozaki, Satoshi, et al.
Publicado: (2022) -
Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study
por: Shinozaki, Satoshi, et al.
Publicado: (2023) -
Normalization of Flow in the Common Hepatic Artery after Decompression of Median Arcuate Ligament Syndrome with Diminution of a Pancreatoduodenal Arcade Aneurysm
por: Matsumoto, Kenji, et al.
Publicado: (2022) -
A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)